Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity

Sarah N Lauder, Philip R Taylor, Stephen R Clark, Rhys L Evans, James P Hindley, Kathryn Smart, Heather Leach, Emma J Kidd, Kenneth J Broadley, Simon A Jones, Matt P Wise, Andrew J Godkin, Valerie O’Donnell, Awen M Gallimore

ABSTRACT

Background Seasonal influenza A infection affects a significant cohort of the global population annually, resulting in considerable morbidity and mortality. Therapeutic strategies are of limited efficacy, and during a pandemic outbreak would only be available to a minority of the global population. Over-the-counter medicines are routinely taken by individuals suffering from influenza, but few studies have been conducted to determine their effectiveness in reducing pulmonary immunopathology or the influence they exert upon the generation of protective immunity.

Methods A mouse model of influenza infection was utilised to assess the efficacy of paracetamol (acetaminophen) in reducing influenza-induced pathology and to examine whether paracetamol affects generation of protective immunity.

Results Administration (intraperitoneal) of paracetamol significantly decreased the infiltration of inflammatory cells into the airway spaces, reduced pulmonary immunopathology associated with acute infection and improved the overall lung function of mice, without adversely affecting the induction of virus-specific adaptive responses. Mice treated with paracetamol exhibited an ability to resist a second infection with heterologous virus comparable with that of untreated mice.

Conclusions Our results demonstrate that paracetamol dramatically reduces the morbidity associated with influenza but does not compromise the development of adaptive immune responses. Overall, these data support the utility of paracetamol for reducing the clinical symptoms associated with influenza virus infection.

INTRODUCTION

Influenza A viruses are responsible for seasonal epidemics accounting for up to 500,000 deaths per annum worldwide; however, the propensity of these viruses to acquire new genetic material from animal reservoirs generates novel pandemic strains with greater morbidity and mortality. The global impact of influenza A has been ever-present throughout the 20th century with the Spanish (1918), Asian (1957) and Hong Kong (1968) influenza pandemics. The 1918–1919 Spanish influenza pandemic was estimated to have infected one-third of the world’s population and accounted for 50–100 million deaths. In early 2009 attention was drawn to the emergence of a new pandemic H1N1 influenza A strain that quickly spread to all continents. Therapeutic strategies for prevention and treatment of influenza A viruses remains a complex problem since animal reservoirs and antigenic shift can create potentially pandemic strains. This makes it difficult and costly to eliminate influenza A or create effective vaccines. Antiviral drugs are the first line of defence against new strains, but these are costly, resistance may occur and availability is limited.

Many factors contribute to the pathophysiology of influenza infection, including direct effects of both the virus and host factors such as the magnitude and type of immune response, and other non-steroidal anti-inflammatory drugs (NSAIDs) are often taken to alleviate symptoms of influenza virus infection. Despite their ubiquitous availability and use, the effects of this group of drugs, including paracetamol, on influenza infection have been poorly investigated. Although widely used, the pharmacotherapeutic effects of paracetamol remain controversial, with some studies suggesting that the drug serves largely as an analgesic while others report additional anti-inflammatory effects (reviewed in Bertolini et al). In support of an anti-inflammatory role, Hinz and colleagues demonstrated that paracetamol inhibits the activity of COX-2, an inducible enzyme that generates prostaglandins (PGs), prostacyclin and thromboxane. The role of this enzyme in influenza infection has been investigated further in COX-2-deficient mice which exhibit attenuated pulmonary inflammation and delayed viral clearance.

Administration of paracetamol might therefore be expected to limit the severity of influenza-induced lung pathology, but this could adversely affect patients by impairing antiviral responses. Furthermore, perturbation of the inflammatory response could impair the development of protective immunity. Although influenza-specific immune responses have not been assessed in COX-2-deficient mice, Prymula et al have reported significantly lower antibody responses to some vaccines in infants receiving prophylactic paracetamol compared with those that did not.

This paper is freely available online under the BMJ Journals unlocked scheme, see http://thorax.bmj.com/site/about/unlocked.shtml

Correspondence to
Sarah N Lauder, Department of Infection, Immunity & Biochemistry, School of Medicine, Heath Park, Cardiff CF14 4XN, UK
laudersn@cardiff.ac.uk
VO and AMG contributed equally to this work.

Received 31 August 2010
Accepted 9 December 2010
In view of the widespread availability of paracetamol and NSAIDs amongst the general population, we sought to examine the effects of paracetamol and a selective COX-2 inhibitor (celecoxib) in a mouse model of influenza virus infection. We hypothesised that administration of these drugs following infection would diminish the immune response, delay virus clearance and reduce immunopathology in target tissues. We further hypothesised that the adaptive immune response would be adversely affected, thereby compromising the establishment of protective immunity. In this study, each hypothesis was addressed by comparing innate and adaptive immune responses, virus clearance, lung pathology and the ability to resist challenge with heterologous influenza virus in both drug-treated and untreated mice.

METHODS

Refer to the Supplementary information for a detailed description regarding the dose selection for celecoxib and paracetamol used during this study, flow cytometric analysis of pulmonary cells and lung intracellular cytokine staining, determination of serum alanine aminotransferase (ALT), quantification of pulmonary PGE2, in vivo lung function, in vitro virus titration and the statistical tests used.

Murine influenza infection model

Female C57BL/6 mice were sourced from Charles River UK and used at 8–10 weeks of age in experimental procedures in compliance with UK Home Office regulations.

Recombinant influenza A virus strains A-PR8-34 (PR8, H1N1) and A/X31 (X31, H3N2) were obtained from the National Institute for Medical Research (NIMR, London, UK). Mice were infected intranasally with 50 plaque-forming units (pfu) of PR8 in 50 μl of sterile phosphate-buffered saline (PBS), under light anaesthesia for primary influenza infection. Mice were injected daily intraperitoneally with either 10 mg/kg of celecoxib or 125 mg/kg paracetamol for 10 days as described in the Supplementary material. Memory recall responses to prior influenza infection were examined by rechallenging previously infected mice at 7–9 weeks after primary PR8 administration. Mice were infected intranasally with 200 pfu of X31 in 50 μl of sterile PBS under light anaesthesia. Body weight was recorded daily during the course of infection until mice were sacrificed or until day 16 for memory studies.

Mice were sacrificed at days 4, 7 and 10 during primary infection and day 4 after rechallenge, and bronchoalveolar lavage (BAL) was performed. Following BAL, lungs were isolated and kept on ice. A detailed description regarding BAL and lung cell isolation is provided in the Supplementary information.

Histopathology

At day 7 postinfection lungs were perfused with 5 ml of PBS and fixed with 10% neutral buffered formalin solution. Following fixation, lungs were embedded in paraffin and 5 μm sections were cut. Sections were stained with H&E and scored blinded. Lungs were scored using modified scoring criteria from Longhi et al.12 and Ashcroft et al.13. The degree of leucocyte infiltration of the airway spaces and the formation of lymphoid aggregates were independently scored on an increasing scale (0–5). These were combined with the extent of perivascular lymphocytic aggregation within each section (0–10), to give a score ranging between 0 and 13. The mean score for each clinical parameter was statistically compared between groups.

Determination of PR8-neutralising antibody titres

Serum was isolated from mice at 7–9 weeks postinfection with PR8 and from naïve uninfected mice. Madin–Darby canine kidney (MDCK) cells at 50% confluence were plated into flat-bottomed 96-well plates and cultured for 48 h in the presence of 720 pfu of PR8 and serum at a 1:8 dilution. Cell viability was calculated using alamar blue (Biosource International, Camarillo, California, USA) according to the manufacturer’s guidelines. The efficacy of serum from influenza-primed mice to neutralise PR8 was compared with the neutralising efficacy of serum from influenza-naive mice.

RESULTS

Celecoxib and paracetamol diminish influenza-associated pulmonary PGE2 and reduce the extent of influenza-induced airway inflammation

The anti-inflammatory effects of NSAIDs such as celecoxib are attributed mainly to their ability to inhibit the activity of COX-2, an enzyme which catalyses the biosynthesis of PGs from arachidonic acid. COX-2 is upregulated during an inflammatory response, thereby increasing levels of PGs, most notably PGE2, a metabolite known to modulate immune cell activity. To determine whether PGE2 in the lungs of influenza-infected mice is COX-2 derived, lipids from lungs of infected mice and infected mice administered either celecoxib or paracetamol were analysed using liquid chromatography/tandem mass spectrometry. Our data indicate that PGE2 is elevated in the lungs of influenza-infected animals compared to uninfected controls (763 ±/− 75ng/mg vs 408 ±/− 128), and that this is inhibited by administration of either celecoxib (376±122 ng/mg) or paracetamol (568±111 ng/mg) (data not shown). These observations indicate that elevated PGE2 following influenza infection is COX-2 derived. A similar extent of PGE2 inhibition was observed with celecoxib and paracetamol, in line with reports of their comparable ability to inhibit PGE2 production in human blood.14

Infection of mice with influenza virus typically results in occlusion of the lung airway spaces by inflammatory cell infiltration. To gain insight into the inflammatory response in the airways, a quantitative analysis of the cellular composition of BAL fluid of infected mice was performed by flow cytometry. As expected, there was a highly significant increase in the numbers of cells recovered from BAL of infected mice compared with uninfected animals (figure 1A–F). Paracetamol administration significantly reduced cell infiltration at days 4, 7 and 10 post-infection. Detailed analysis showed significantly fewer neutrophils, inflammatory monocytes, eosinophils and natural killer (NK) cells in the BAL of paracetamol-treated animals compared with untreated mice (figure 1C–F). A similar pattern was observed in the celecoxib-treated group where a trend for fewer cells was observed at each time point, although in this case a statistically significant difference was observed only at day 10. Overall, these data imply a protective effect of paracetamol in reducing the extent of influenza-induced immunopathology.

Airway function is improved in mice receiving celecoxib and paracetamol

The observation that inflammation is reduced by paracetamol administration is further supported by an analysis of airway function in the same groups of mice. A group of influenza-infected, untreated control animals and animals treated with either paracetamol or celecoxib were subjected to airway function tests performed by whole-body plethysmography. This technique measures changes in air pressure as a result of
Figure 1  Effect of celecoxib or paracetamol upon influenza-induced airway inflammation and immunopathology. Bronchoalveolar lavage (BAL) fluid was aspirated at day 4, 7 or 10 postinfection and the airway-infiltrating cells were isolated. The total numbers of cells (A) and the numbers of alveolar macrophages (B), neutrophils (C), inflammatory monocytes (D), eosinophils (E) and natural killer (NK) cells (F) at the selected time points were determined by flow cytometry. (G) At day 7 postinfection, airway hyper-responsiveness to inhaled methacholine (10 mg/ml for 5 min) was determined by measuring changes in Penh (enhanced pause) 5 min after methacholine challenge, expressed as a percentage of the premethacholine baseline. Changes in Penh were measured from naive mice, used as an uninfected control, and virus-infected mice treated or not with celecoxib or paracetamol. Results are expressed as the mean±SEM for each group, n=6 mice/group. The significance of differences between drug-treated and untreated mice was assessed using one-way analysis of variance with Tukey–Kramers post hoc multicomparison test (A–F) and between infected and uninfected mice using an unpaired t test (G), *p<0.05; **p<0.01; ***p<0.001.
inspiration and expiration. In these experiments, enhanced pause (Penh), a measurement of changes in expiratory effort, was used as an indicator of airway obstruction. Specifically, control and drug-treated animals infected 7 days previously with influenza virus were challenged with aerosolised methacholine (10 mg/ml) and Penh was measured. There was a significant increase in the peak Penh response in all infected mice compared with uninfected controls; however, this difference was less pronounced in celecoxib- and particularly paracetamol-treated mice (figure 1G).

To assess if this improvement in lung function corresponded to a reduction in influenza-induced pulmonary immunopathology, lungs, recovered at day 7 postinfection, were assessed histologically. Extensive leukocyte infiltration (figure 2A,C) and perivascular aggregation (figure 2B,D) were observed in all influenza-infected animals, when compared with uninfected control animals. These observations, while not significantly different between drug-treated and untreated mice, when combined with a notable improvement in lung function in paracetamol-treated mice, imply a marked reduction in influenza-associated pathology during the acute stages of infection.

The effects of celecoxib or paracetamol on influenza-induced liver dysfunction

Influenza infection of humans can be associated with an increase in serum ALT levels and a transient and self-limiting hepatitis. Studies of mouse models of influenza infection indicate that liver injury during influenza infection is not attributable to influenza infection of the liver but rather represents collateral damage caused by antigen-independent sequestration of immune cells, most notably influenza-specific CD8+ T cells in the liver. We sought to determine whether ALT levels were increased in the serum of influenza-infected mice at day 7 postinfection and whether this was reduced by administration of paracetamol or celecoxib. The results, shown in figure 3A, indicate that both drugs virtually abolished influenza-induced increases in ALT levels. Weight loss is also commonly used as an indicator of the severity of influenza-induced pathology. However, we observed no change in weight loss following influenza infection as a consequence of celecoxib or paracetamol administration (figure 3B and Supplementary figure 1).

Figure 2  Histological analysis of pulmonary sections from treated and untreated mice postinfection with influenza virus. Lungs were harvested from mice at day 7 postinfection and, following perfusion, were formalin fixed, embedded in paraffin wax, sectioned and stained with H&E. (A and B) Representative sections depicting pulmonary leukocytes from influenza-infected, treated and untreated mice were compared with uninfected mice (original magnification×10 (A)) Arrowheads highlight areas of lymphocytic perivascular aggregate (original magnification×20 (B)). The mean score±SEM for each group is given, n=6 mice/group for the severity of influenza infiltrate (C) and degree of perivascular lymphoid aggregate (D). The significance of differences between influenza-infected mice and uninfected mice was determined using one-way analysis of variance with Tukey–Kramers multicomparison test, *p<0.05; **p<0.01.
Figure 3 Effect of cyclo-oxygenase 2 (COX-2) inhibition upon clinical parameters of primary influenza infection. (A) Serum collected from mice at day 7 postinfection was used to determine circulating alanine aminotransferase (ALT) levels during acute influenza infection. Results are expressed as the mean±SEM, n=6–16 mice/group. (B) Post-PR8 infection mice were weighed daily for 16 days, and changes in body weight were expressed as a percentage of their starting weight. Each data point represents the mean±SEM, n=–6 mice/group. The significance of differences between drug-treated and untreated mice was assessed using one-way analysis of variance with post hoc Tukey–Kramer multiple mean comparison,*p<0.05; **p<0.01; ***p<0.001.

Virus clearance is unimpaired in celecoxib- or paracetamol-treated mice
As paracetamol and, to a lesser extent, celecoxib reduces the magnitude of the inflammatory response to influenza virus, we hypothesised that viral clearance would be delayed in these animals compared with non-treated controls. Viral titres in the lungs of influenza-infected mice declined on days 7 and 10 compared with day 4 postinfection. Surprisingly we observed no significant differences in viral titres among the groups at any of the time points analysed (figure 4).

Protective immunity is not impaired in mice treated with paracetamol or celecoxib during primary infection with influenza virus
A reduction in influenza-induced innate immune responses as a consequence of celecoxib or paracetamol treatment could alter the magnitude of the virus-specific adaptive immunity. To investigate this, interferon γ (IFNγ)- and tumour necrosis factor α (TNFα)-producing CD4+ and CD8+ T cells in the lungs were measured at day 10 postinfection. The number of cytokine-producing cells was, as expected, elevated as a result of the infection, but there was no statistically significant difference between influenza-infected groups treated or not with drugs...
Influenza infection caused airway hyper-responsiveness to the inhaled spasmogen, methacholine, in agreement with previous reports, which was reduced following treatment with paracetamol or celecoxib. Thus, paracetamol appears to play a protective role, reducing lung pathology and helping to preserve lung function. Patients infected with seasonal influenza A, who subsequently develop severe respiratory failure, are characterised by a profound early inflammatory infiltrate and cytokine release. The same was true for the 2009 novel H1N1 influenza A pandemic where severe lung injury occurred in young adults in whom it was frequently difficult to maintain oxygenation. Autopsies on patients succumbing to this new influenza strain showed pulmonary pathology similar to previous pandemics, with profound cellular infiltrates and diffuse alveolar damage. Thus paracetamol may, through inhibition of COX-2, afford protection for patients infected with influenza and complicated by respiratory failure through attenuation of the proinflammatory response. The importance of the COX-2 pathway in severe respiratory failure is further substantiated by experiments using avian H5N1 influenza A virus. Avian H5N1 infection has a case death approaching 30% but is not transmissible between humans; it is characterised by severe respiratory failure with inflammatory infiltrates within the lung and high levels of inflammatory cytokines such as TNFα and IFNγ. Compared with seasonal H1N1 influenza A virus, avian H5N1 differentially upregulates COX-2 in primary human macrophages in vitro and epithelial cells in vivo, the increased expression resulting from autocrine or paracrine

\[ \text{Days Post Infection} \]

**Figure 6** Protective immune responses to secondary influenza infection. (A and B) At 7–9 weeks postinfection mice were rechallenged with 200 plaque-forming units (pfu) of X31. (A) Mice were weighed prior to secondary infection to provide a baseline 100% starting weight and for 4 days thereafter. Each data point represents the mean±SEM for each group, n=3–6 mice/group. (B) At day 4 after secondary infection, mice were sacrificed and the lungs were harvested following perfusion with phosphate-buffered saline. Lungs were homogenised and the viral load was determined using the previously described MDCK (Madin–Darby canine kidney) plaque assay. Plots represent the mean of each group±SEM, n=6 mice/group, 3 mice/group for PR8-naive mice. The significance of differences between previously PR8-infected mice and PR8-naive mice was evaluated using one-way analysis of variance with Tukey–Kramer multiple comparison post hoc test, \(**, p<0.001.\)
mediators rather than direct effects of the virus.19 Expression of inflammatory cytokines is driven by COX-2 upregulation and can be effectively inhibited with selective COX-2 inhibitors.19 In another murine model of avian H5N1 infection, addition of the selective COX-2 inhibitor celecoxib to the neuraminidase inhibitor zanamivir reduced lung inflammation and virus titres and increased survival from 13.3% to 55.3% and mean survival time from 8.4 to 13.3 days compared with zanamivir alone.22 It is clear from this study and our own that attenuating the inflammatory response to influenza does not compromise virus clearance. Indeed, overall we observed a trend for better virus control in the treated animals. Overall these data support a protective role for paracetamol during the acute stage of infection with influenza virus. We considered it important that the impact of paracetamol administration at this time on the generation of influenza-specific responses was also assessed. As the innate immune response influences the development of the adaptive response, attenuation of this response through the effects of paracetamol could suppress the virus-specific immune response. In addition, PGE2 has been shown in vivo to promote T helper 1 (Th1) cell differentiation, thus inhibition of PGE2 could directly downmodulate development of influenza-specific T cell and antibody responses.23 In support of this, a recent report detailing antibody responses in 226 infants receiving vaccines demonstrated significantly lower antibody titres in those receiving prophylactic paracetamol.11 Our data clearly show, however, no significant differences in the influenza-specific immune response in drug-treated and untreated animals. Importantly, the ability of drug-treated mice to resist rechallenge with a heterotypic influenza virus was unimpaired.

The current study demonstrates that both paracetamol and celecoxib, which inhibit COX-2, attenuate pulmonary inflammation without impeding virus clearance or the development of specific immunity in mice. While the doses of paracetamol used are different for mice and humans, as described in the Supplementary material, the implications of the study are clear. Over-the-counter medicines such as paracetamol, which inhibit COX-2, are cheap, widely available and target the host response rather than the virus, and therefore offer an attractive therapeutic option.24 However, with the information currently available on the effects of paracetamol upon influenza infection, it is possible that its impact may differ in mice and humans. It is important that these observations, generated using a mouse model, are validated with respect to the action of paracetamol and its impact on the immune system in clinical studies of human influenza virus infection.

Acknowledgements The authors would like to thank Dr Emma Jones for her expertise with the histological images in figure 2, Dr Sivassanaka Balasubramanian for assistance in performing the experiments in figure 1, Dr Mike Badminton for facilitating the measurements of alanine transaminase, and Mr Lloyd Morgan for providing assistance in the generation of preliminary data for the study.

Funding This work was supported by a Wellcome Trust project grant (080340), an MRC Senior Non-Clinical Fellowship awarded to AMS (G117/488) and PRT (G0601617), and a European Union Marie Curie Fellowship awarded to SRC.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Murray CJ, Lopez AD, Chin B, et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis. Lancet 2009;363:2211–16.

2. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197–201.

3. Conn CA, McClean JL, Maassab HF, et al. Cytokines and the acute phase response to influenza virus in mice. Am J Physiol 1995;268:R78–84.

4. Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 2008;172:1155–70.

5. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine 2009;27(Suppl 1):D9–66.

6. Perrone LA, Fawden JK, Garcia-Sastre A, et al. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 2008;4:e1000115.

7. Bertolini A, Ferrari A, Ottani A, et al. Paracetamol: new vistas of an old drug. CNS Drug Rev 2006;12:259–75.

8. Hinz B, Dhemenma O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22:833–90.

9. Carey MA, Bradbury JA, Seubert JM, et al. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005;175:8785–94.

10. Graham NM, Burrell CJ, Douglas RM, et al. Adverse effects of aspirin, paracetamol, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990;162:277–82.

11. Prymula R, Siegrist CE, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009;374:1339–50.

12. Longhi MP, Williams A, Wise M, et al. COX5a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms. Eur J Immunol 2007;37:1268–74.

13. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467–70.

14. Polakos NK, Carnejo JC, Murray DA, et al. Kupffer cell-dependent hepatitis occurs during influenza infection. Am J Pathol 2006;168:1188–98; quiz 1404–5.

15. Bezanich EM, Gualano RC, Zosky GR, et al. Acute Influenza A infection induces bronchial hyper-responsiveness in mice. Respir Physiol Neurobiol 2008;162:190–6.

16. Bautista E, Chatpatayawarndh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2009;362:1708–19.

17. Gill JR, Sheng ZM, Ely SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2009;133:235–43.

18. Mauad T, Hajar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2009;180:712–9.

19. Lee SM, Cheung CY, Nicholls JM, et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 2008;198:525–35.

20. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831–7.

21. Lee SM, Gandy JL, Cheung CY, et al. Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. PLoS ONE 2009;4:e8072.

22. Zheng BJ, Chan KW, Lin YP, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2006;103:8091–6.

23. Bloom ET, Babbit JT, Prostaglandin E2, monocyte adherence and interleukin-1 in the regulation of human natural killer cell activity by monocytes. Nat Immun Cell Growth Regul 1990;9:36–48.

24. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008;8:571–6.
Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity

Sarah N Lauder, Philip R Taylor, Stephen R Clark, Rhys L Evans, James P Hindley, Kathryn Smart, Heather Leach, Emma J Kidd, Kenneth J Broadley, Simon A Jones, Matt P Wise, Andrew J Godkin, Valerie O'Donnell and Awen M Gallimore

Thorax published online February 10, 2011

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2011/02/09/thx.2010.150318

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2011/01/19/thx.2010.150318.DC1
http://thorax.bmj.com/content/suppl/2011/02/07/thx.2010.150318.DC2

References
This article cites 24 articles, 7 of which you can access for free at:
http://thorax.bmj.com/content/early/2011/02/09/thx.2010.150318#BIBL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (251)
Influenza (106)
TB and other respiratory infections (1273)
Epidemiologic studies (1829)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
